drugset / Trial / NCT03614156
Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) or 225 mg of Rapastinel compared to placebo in the prevention of relapse in participants with major depressive disorder (MDD).
Timeline
- Start
- 2018-08-02
- Primary completion
- 2019-07-11
- Completion
- 2019-07-11
Outcome
Outcome not reported
Stopped (Business): “Business decision to stop the program.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rapastinel | Other / unclassified | 225 mg | Intravenous |
| Subject | Rapastinel | Other / unclassified | 450 mg | Intravenous |